Atlas Trials

Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer

Clinical trial NCT02768701 · COMPLETED

Trial details

NCT number
NCT02768701
Sponsor
UNC Lineberger Comprehensive Cancer Center
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Triple Negative Breast Cancer
Start date
2016-10-18
Primary completion
2022-05-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.